Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 700Neoplasms 621Prostatic Neoplasms 322Lung Neoplasms 314Colorectal Neoplasms 284Carcinoma, Non-Small-Cell Lung 260Pancreatic Neoplasms 181Carcinoma, Hepatocellular 171Stomach Neoplasms 141Multiple Myeloma 127Ovarian Neoplasms 123Melanoma 118Colonic Neoplasms 114Brain Neoplasms 111Hematologic Neoplasms 107Urinary Bladder Neoplasms 104Head and Neck Neoplasms 104Leukemia, Myeloid, Acute 102Esophageal Neoplasms 100Disease 100Uterine Cervical Neoplasms 91Liver Neoplasms 91Neoplasm Metastasis 89Lymphoma 86Rectal Neoplasms 84Precursor Cell Lymphoblastic Leukemia-Lymphoma 84Endometrial Neoplasms 79Carcinoma, Renal Cell 74Leukemia 65Recurrence 63

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × HER2 Overexpression × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡